Liver failure associated with benzbromarone: A case report and review of the literature

Table 2 Characteristics of benzbromarone-induced hepatotoxicity cases

Age	Sex	Course of benzbro-marone	Dose	Combined medication	Prior liver diseases	Other diseases	Treatment	Outcome	Ref.
68	F	3.5 mo	200 mg/d (6 wk); 100 mg/d (2 mo)	Methyldopa	-	Gout, hypertension	Conservative treatment	Recovery (24 d)	[17]
62	M	6 mo	75 mg/d	-	-	Hyperurice-mia	Bilirubin absorption	Death(62 d)	[18]
58	M	2 mo	Not described	Allopurinol, tocopherol, nicotinate, alprazolam, theophylline, azelastine hydrochloride, nilvadipine alcohol: (approximately 36 g/d)	-	Hyperurice-mia, hypertension, asthmatic bronchitis	PE + HDF, prednisolone (30 mg/d orally, reduced gradually)	Recovery (94 d)	[19]
53	F	2 mo	100 mg/d	Allopurinol	-	Hyperurice-mia, proteinuria	Liver transplant	Death (124 d)	[20]
53	M	3 d	50 mg/d	-	-	Hyperurice-mia, diabetes	Conservative treatment	Recovery (3 d)	[21]
77	F	4 mo	Not described	Torsemide, nebivolol, ramipril, thyronajod	-	Hypertension, hyperthyroid disease, adiposity	Conservative treatment	Death (53 d)	[22]
59	M	More than 1 yr	50 mg/d	Benidipine, pravastatin, alcohol (60 g/ d)	Liver dysfunction	Hyperurice-mia, hypertension, dyslipidemia	HDF, liver transplant	Recovery (70 d)	[23]
47	M	15 d	Not described	Thiopronin	NAFLD	Gout, diabetes, hyperlipide-mia	Methylprednisolone (8 mg/d orally)	Recovery (70 d)	[24]
39	M	4 mo	100 mg/d	Alcohol: (approximately 28 g/d for 10 yr)	-	Gout	PE + liver transplant	Recovery

HDF: Hemodiafiltration; NAFLD: Non-alcoholic fatty liver disease; PE: Plasma exchange; M: Male; F: Female.